Monoamine Oxidase Inhibitors

• 

  Subject Areas on Research

  • A history of the concept of atypical depression. 
  • A history of the concept of atypical depression. 
  • A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study. 
  • A systematic review of newer pharmacotherapies for depression in adults: evidence report summary. 
  • Acetylenics. 2. Synthesis and pharmacology of certain N,N-diakyl-3-phenylpropyn-2-amines. Some analogues with tryptamine-like behavioral effects in mice. 
  • Adding a tricyclic antidepressant to a monoamine oxidase inhibitor. 
  • Anti-inflammatory effects of inhibiting the amine oxidase activity of semicarbazide-sensitive amine oxidase. 
  • Antidepressant use in elderly medical inpatients: lessons from an attempted clinical trial. 
  • Atypical depression. 
  • Biological therapies for posttraumatic stress disorder: an overview. 
  • Catecholamine release and uptake in the mouse prefrontal cortex. 
  • Cerebral amino acid, norepinephrine and nitric oxide metabolism in CNS oxygen toxicity. 
  • Clorgyline and deprenyl attenuate striatal malonate and 3-nitropropionic acid lesions. 
  • Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. 
  • Defining an appropriate management strategy for social anxiety disorder. 
  • Differential effects of non-nicotine tobacco constituent compounds on nicotine self-administration in rats. 
  • Does dopamine contribute to striatal damage caused by impaired mitochondrial function? 
  • Efficacy and safety of selegiline transdermal system (STS) for the atypical subtype of major depressive disorder: pooled analysis of 5 short-term, placebo-controlled trials. 
  • Efficacy of newer medications for treating depression in primary care patients. 
  • Forms of atypical depression and their response to antidepressant drugs. 
  • Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. 
  • Increased tonic activation of rat forebrain 5-HT(1A) receptors by lithium addition to antidepressant treatments. 
  • International advances in the treatment of social phobia. 
  • Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial. 
  • Long-term outcome of early versus delayed rasagiline treatment in early Parkinson's disease. 
  • MAO inhibition and control of anxiety following amitriptyline therapy. A pilot study. 
  • Medical treatment of Parkinson disease. 
  • Moclobemide in social phobia: a controlled dose-response trial. 
  • Monoamine mediation of the morphine-induced activation of mice. 
  • Monoamine oxidase inhibitors in patients with chronic pain. 
  • Monoamine precursors in the treatment of depression. 
  • Neuroticism and personality disorder in depression. 
  • Patient compliance with MAO inhibitor therapy. 
  • Pharmacotherapy of posttraumatic stress disorder: treatment options, long-term follow-up, and predictors of outcome. 
  • Pharmacotherapy of social anxiety disorder. 
  • Pharmacotherapy of social phobia. 
  • Platelet MAO inhibition following tricyclic antidepressant therapy. 
  • Practical aspects of MAO inhibitor therapy. 
  • Predictors of relapse in patients with major depressive disorder in a 52-week, fixed dose, double blind, randomized trial of selegiline transdermal system (STS). 
  • Predictors of response to monoamine oxidase inhibitors: do they exist? 
  • Predictors of treatment response in patients with posttraumatic stress disorder. 
  • Prevention of H2O2 generation by monoamine oxidase protects against CNS O2 toxicity. 
  • Quantitative measurement of postural sway in mouse models of human neurodegenerative disease. 
  • Relapse, side effects, and monoamine oxidase inhibition during long term use of isocarboxazid: a case report. 
  • Revisiting monoamine oxidase inhibitors. 
  • Revisiting the Cartesian model of pain. 
  • Safety of selegiline transdermal system in clinical practice: analysis of adverse events from postmarketing exposures. 
  • Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial. 
  • Selegiline transdermal system: current awareness and promise. 
  • Single-blind, placebo phase-in trial of two escalating doses of selegiline in the chronic fatigue syndrome. 
  • Social phobia: biological aspects and pharmacotherapy. 
  • Social phobia: issues in assessment and management. 
  • The Newcastle Anxiety Depression Diagnostic Index in relationship to the effects of monoamine oxidase inhibitors and tricyclic antidepressants. 
  • Tobacco leaf, smoke and smoking, MAO inhibitors, Parkinson's disease and neuroprotection; are there links? 
  • Transdermal selegiline. 
  • Transdermal selegiline: the new generation of monoamine oxidase inhibitors. 
  • Tribulin in post-traumatic stress disorder. 
  • Urinary metabolities of harmine in the rat and their inhibition of monoamine oxidase. 
  • trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1.